Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ptc Therapeutics (PTCT) EBT: 2011-2024

Historic EBT for Ptc Therapeutics (PTCT) over the last 14 years, with Dec 2024 value amounting to -$598.8 million.

  • Ptc Therapeutics' EBT rose 76.45% to -$23.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $505.3 million, marking a year-over-year increase of 198.29%. This contributed to the annual value of -$598.8 million for FY2024, which is 23.69% up from last year.
  • As of FY2024, Ptc Therapeutics' EBT stood at -$598.8 million, which was up 23.69% from -$784.7 million recorded in FY2023.
  • Ptc Therapeutics' 5-year EBT high stood at -$452.5 million for FY2020, and its period low was -$784.7 million during FY2023.
  • In the last 3 years, Ptc Therapeutics' EBT had a median value of -$598.8 million in 2024 and averaged -$658.2 million.
  • In the last 5 years, Ptc Therapeutics' EBT tumbled by 88.59% in 2020 and then rose by 23.69% in 2024.
  • Over the past 5 years, Ptc Therapeutics' EBT (Yearly) stood at -$452.5 million in 2020, then decreased by 14.56% to -$518.3 million in 2021, then decreased by 14.04% to -$591.1 million in 2022, then tumbled by 32.75% to -$784.7 million in 2023, then climbed by 23.69% to -$598.8 million in 2024.